Biotechnology

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

Genomic pioneer Sangamo sells key assets to PTC and Lilly in a $163M bankruptcy deal, reshaping the future of gene therapy and rare disease treatment.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

South Korea's PharmaResearch is strategically embedding its REJURAN skin booster in Australia, moving beyond sales to reshape aesthetics with science and education.

Niagen Bioscience heads to a key investor conference. Can its CFO translate the complex science of healthy aging into a compelling story for market growth?

Amprion's expansion of its alpha-synuclein test to Europe isn't just a deal; it's the build-out of a new infrastructure for understanding the brain.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

With wheat prices soaring, a new biosolution from Novonesis allows pasta makers to de-risk supply chains by using common wheat, securing a global staple.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

RyboDyn's RyboCypher platform is uncovering a 'dark proteome' full of tumor-specific targets, promising a new era beyond today's crowded drug pipeline.

Amid a selective biotech market, Rakovina Therapeutics' oversubscribed placement highlights investor belief in its AI-powered strategy for next-gen cancer drugs.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

As VolitionRx readies its Q2 update, investors and scientists look for proof that its pioneering epigenetic tests can translate into commercial success.

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.